STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Nantahala Discloses 189,705 Shares in Kiora; Warrants Included

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Nantahala Capital Partners reported beneficial ownership of 189,705 shares of Kiora Pharmaceuticals common stock, representing 5.299% of the outstanding shares as of August 8, 2025. The filing states that 146,533 of those shares may be acquired within 60 days through the exercise of warrants, and Nantahala holds shared voting and dispositive power over the full 189,705 shares while holding no sole voting or dispositive power. The ownership percentage is calculated using 3,433,491 shares outstanding per Kiora's Form 10-Q filed August 8, 2025. The filing includes certifications that the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.

Positive

  • Clear disclosure of a 5.299% beneficial ownership exceeding the 5% reporting threshold
  • Includes exercisable warrants (146,533 shares) within 60 days, which explains part of the reported position

Negative

  • None.

Insights

TL;DR: Nantahala reports a 5.299% stake in Kiora, including warrants that vest within 60 days; holdings are disclosed as shared authority.

This Schedule 13G discloses a meaningful passive position at just over the 5% threshold, with 146,533 shares exercisable via warrants within 60 days, which explains part of the reported position. The filing indicates shared voting and dispositive power for the entire position and explicitly states the stake was acquired in the ordinary course of business, not to influence control. For investors, the key numbers are the 189,705 total shares and the 3,433,491 share base used to calculate the 5.299% ownership.

TL;DR: This is a routine Schedule 13G disclosure showing passive ownership above 5% with warrants included; no control intent stated.

The filing follows Rule 13d-1 reporting requirements for a passive investor crossing the 5% threshold. It clarifies that Nantahala has shared voting and dispositive power but disclaims any intent to change or influence control. The inclusion of exercisable warrants within 60 days is material to the percentage calculation and should be noted by governance stakeholders monitoring significant passive positions. No group affiliations or additional parties are identified.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer Nantahala Capital Management, LLC
Date:08/14/2025
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey / Manager Nantahala Capital Management, LLC
Date:08/14/2025
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack / Manager Nantahala Capital Management, LLC
Date:08/14/2025

FAQ

How many Kiora (KPRX) shares does Nantahala beneficially own?

Nantahala beneficially owns 189,705 shares of Kiora common stock as of August 8, 2025.

What percentage of Kiora does Nantahala own according to the filing?

The filing reports Nantahala owns 5.299% of Kiora's outstanding shares based on 3,433,491 shares outstanding.

Does the reported position include any exercisable securities?

Yes, the 189,705 shares include 146,533 shares that may be acquired within 60 days through exercise of warrants.

Does Nantahala claim intent to influence control of Kiora?

No. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

What voting and dispositive powers does Nantahala have over these shares?

Nantahala reports 0 sole voting power and 189,705 shared voting power; likewise 0 sole dispositive power and 189,705 shared dispositive power.
KIORA PHARMACEUTICALS INC

NASDAQ:KPRX

KPRX Rankings

KPRX Latest News

KPRX Latest SEC Filings

KPRX Stock Data

6.91M
3.57M
3.19%
25.28%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
ENCINITAS